Sparstolonin B, a selective TLR2 and TLR4 antagonist, is an isocoumarin compound isolated from the tubers of Sparganium stoloniferum and Scirpus yagara with anti-HIV, anticancer, antitumour and anti-inflammatory activities, inhibits selective Toll-like receptors, inhibits free fatty acids It inhibits selective Toll-like receptors, inhibits free fatty acid palmitate-induced chondrocyte inflammation and attenuates post-traumatic arthritis in obese mice, and inhibits lipopolysaccharide-induced inflammation in 3T3-L1 adipocytes, which can be used for validation and mammary carcinoma studies.

Sparstolonin B (1-20 μM; 2-4 days) inhibits cell growth and viability of neuroblastoma cells[3].Sparstolonin B inhibits TLR ligand-induced cytokine expression in mouse macrophages. Sparstolonin B inhibits MyD88 recruitment to TLR4 and TLR2[1].Sparstolonin B generates reactive oxygen species (ROS) in neuroblastoma cells. Sparstolonin B reduces expression of N-myc in neuroblastoma cells[3]. Cell Viability Assay[3] Cell Line: SH-SY5Y, IMR-32, NGP, SKNF-1 and SK-N-BE(2) cells

Sparstolonin B (100 μg/mouse; i.p.) suppresses LPS-induced inflammation in 5-6-week-old male C57Bl/6 mice (18-20 g body weight)[1].